Blood use in patients receiving intensive chemotherapy for acute leukemia or hematopoietic stem cell transplantation: the impact of a health system–wide patient blood management program

Transfusion

Volumn 57, Issue 9, 2017, Pages 2189-2196

  Leahy, Michael F ^a,c   Trentino, Kevin M ^d   May, Colleen ^c   Swain, Stuart G ^d   Chuah, Hun ^c   Farmer, Shannon L ^b,e  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

^d South Metropolitan Health Service   (Australia)

^e CURTIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN;

ACUTE LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLEEDING; CANCER CHEMOTHERAPY; CHEMOTHERAPY; COST CONTROL; ERYTHROCYTE TRANSFUSION; FEMALE; FOLLOW UP; HEALTH CARE SYSTEM; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HOSPITAL MORTALITY; HUMAN; INTENSIVE CHEMOTHERAPY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; TERTIARY CARE CENTER; THROMBOCYTE TRANSFUSION; WESTERN AUSTRALIA; AUSTRALIA; BLOOD BANK; BLOOD TRANSFUSION; CLINICAL TRIAL; ECONOMICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA; MORTALITY; MULTICENTER STUDY; PROCEDURES; STANDARDS; UTILIZATION;

AUSTRALIA; BLOOD BANKS; BLOOD TRANSFUSION; ERYTHROCYTE TRANSFUSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBINS; HEMORRHAGE; HOSPITAL MORTALITY; HUMANS; LEUKEMIA; PLATELET TRANSFUSION; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS;

EID: 85021736073     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14191     Document Type: Article

References (42)

1. Leahy MF, Hofmann A, Towler S, et al. Improved outcomes and reduced costs associated with a health-system-wide patient blood management program: a retrospective observational study in four major adult tertiary care hospitals. Transfusion 2017;57:1347-58.
2. Farmer SL, Towler SC, Leahy MF, et al. Drivers for change: Western Australia Patient Blood Management Program (WA PBMP), World Health Assembly (WHA) and Advisory Committee on Blood Safety and Availability (ACBSA). Best Pract Res Clin Anaesthesiol 2013;27:43-58.
3. Waters JH, Ness PM. Patient blood management: a growing challenge and opportunity. Transfusion 2011;51:902-3.
4. Patient blood management guidelines [Internet]. Canberra: National Blood Authority; [cited 2017 Jan 17]. Available from: https://www.blood.gov.au/pbm-guidelines.
5. Hofmann A, Ozawa S, Farrugia A, et al. Economic considerations on transfusion medicine and patient blood management. Best Pract Res Clin Anaesthesiol 2013;27:59-68.
6. Isbister JP, Shander A, Spahn DR, et al. Adverse blood transfusion outcomes: establishing causation. Transfus Med Rev 2011;25:89-101.
7. Shander A, Fink A, Javidroozi M, et al. Appropriateness of allogeneic red blood cell transfusion: the international consensus conference on transfusion outcomes. Transfus Med Rev 2011;25:232-46.e53.
8. Trentino KM, Farmer SL, Swain SG, et al. Increased hospital costs associated with red blood cell transfusion. Transfusion 2015;55:1082-9.
9. Cannas G, Fattoum J, Raba M, et al. Transfusion dependency at diagnosis and transfusion intensity during initial chemotherapy are associated with poorer outcomes in adult acute myeloid leukemia. Ann Hematol 2015;94:1797-806.
10. Farmer S, Trentino K, Hofmann A, et al. A programmatic approach to patient blood management – reducing transfusions and improving patient outcomes. Open Anesthesiol J 2015;9:6-16.
11. Pine AB, Lee EJ, Sekeres M, et al. Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. Transfusion 2017;57:289-95.
12. Berger MD, Gerber B, Arn K, et al. Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantation. Haematologica 2012;97:116-22.
13. Hofmann A, Farmer S, Shander A. Five drivers shifting the paradigm from product-focused transfusion practice to patient blood management. Oncologist 2011;16 Suppl 3:3-11.
14. Jansen AJ, Caljouw MA, Hop WC, et al. Feasibility of a restrictive red-cell transfusion policy for patients treated with intensive chemotherapy for acute myeloid leukaemia. Transfus Med 2004;14:33-8.
15. Micolonghi T, Simon S, Paull A, et al. The single-unit transfusion in a community hospital—a critical evaluation. Improved blood transfusion practices may result in increased incidence of single-unit transfusions. R I Med J 1966;49:533-6.
16. Boraless H, Rao MP, Morgan C, et al. A survey of physicians' attitudes to transfusion practice in critically ill patients in the UK. Anaesthesia 2002;57:584-8.
17. Hébert PC, Wells G, Martin C, et al. A Canadian survey of transfusion practices in critically ill patients. Transfusion Requirements in Critical Care Investigators and the Canadian Critical Care Trials Group. Crit Care Med 1998;26:482-7.
18. Isbister JP. The three-pillar matrix of patient blood management—an overview. Best Pract Res Clin Anaesthesiol 2013;27:69-84.
19. Farmer S, Towler S, Hofmann A. The Australian PBM concept—a success story. In: Gombotz H, Zacharowski K, Spahn D, editors. Patient blood management. Stuttgart: Thieme; 2016. p. 207-17.
20. Leahy MF, Roberts H, Mukhtar SA, et al. A pragmatic approach to embedding patient blood management in a tertiary hospital. Transfusion 2014;54:1133-45.
21. Practice strategies for elective red blood cell transfusion. American College of Physicians. Ann Intern Med 1992;116:403-6.
22. Patient blood management guidelines: module 1—critical bleeding/massive transfusion. Canberra: National Blood Authority; 2011.
23. Hofmann A, Farmer S, Towler SC. Strategies to preempt and reduce the use of blood products: an Australian perspective. Curr Opin Anaesthesiol 2012;25:66-73.
24. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9.
25. What blood products are supplied—national product list [Internet]. Canberra: National Blood Authority; [cited 17 Jan 2017]. Available from: https://www.blood.gov.au/national-product-list.
26. Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence—what is it and what can it tell us? N Engl J Med 2016;375:2293-7.
27. McCambridge J, Witton J, Elbourne DR. Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects. J Clin Epidemiol 2014;67:267-77.
28. Stanworth SJ, Estcourt LJ, Powter G, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med 2013;368:1771-80.
29. Blair SD, Janvrin SB, McCollum CN, et al. Effect of early blood transfusion on gastrointestinal haemorrhage. Br J Surg 1986;73:783-5.
30. Hearnshaw SA, Logan RF, Palmer KR, et al. Outcomes following early red blood cell transfusion in acute upper gastrointestinal bleeding. Aliment Pharmacol Ther 2010;32:215-24.
31. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013;368:11-21.
32. Subramaniam K, Spilsbury K, Ayonrinde OT, et al. Red blood cell transfusion is associated with further bleeding and fresh-frozen plasma with mortality in nonvariceal upper gastrointestinal bleeding. Transfusion 2016;56:816-26.
33. Sieunarine K, Lawrence-Brown MM, Brennan D, et al. The quality of blood used for transfusion. J Cardiovasc Surg 1992;33:98-105.
34. Blumberg N, Heal JM, Liesveld JL, et al. Platelet transfusion and survival in adults with acute leukemia. Leukemia 2008;22:631-5.
35. Shander A, Hofmann A, Ozawa S, et al. Activity-based costs of blood transfusions in surgical patients at four hospitals. Transfusion 2010;50:753-65.
36. Shander A, Ozawa S, Hofmann A. Activity-based costs of plasma transfusions in medical and surgical inpatients at a US hospital. Vox Sang 2016;111:55-61.
37. Ford PA, Grant SJ, Mick R, et al. Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. J Clin Oncol 2015;33:1674-9.
38. Leahy MF, Mukhtar SA. From blood transfusion to patient blood management: a new paradigm for patient care and cost assessment of blood transfusion practice. Intern Med J 2012;42:332-8.
39. Mukhtar SA, Leahy MF, Trentino K, et al. Effectiveness of a patient blood management data system in monitoring blood use in Western Australia. Anaesth Intensive Care 2013;41:207-15.
40. Wells AW, Mounter PJ, Chapman CE, et al. Where does blood go? Prospective observational study of red cell transfusion in north England. BMJ 2002;325:803.
41. Le Viellez A, P'Ng S, Buffery S, et al. Red cell and platelet transfusion burden following myeloablative allogeneic haemopoietic stem cell transplantation. Intern Med J 2015;45:1286-92.
42. Shander A, Hofmann A, Gombotz H, et al. Estimating the cost of blood: past, present, and future directions. Best Pract Res Clin Anaesthesiol 2007;21:271-89.